Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis

Bok, 2021, Accelerated COVID-19 vaccine development: milestones, lessons, and prospects, Immunity, 54, 1636, 10.1016/j.immuni.2021.07.017

Wang, 2021, Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7, Nature, 593, 130, 10.1038/s41586-021-03398-2

Planas, 2021, Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization, Nature, 596, 276, 10.1038/s41586-021-03777-9

Liu, 2021, Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum, Cell, 184, 4220, 10.1016/j.cell.2021.06.020

Madhi, 2021, Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant, N Engl J Med, 384, 1885, 10.1056/NEJMoa2102214

Sheikh, 2021, SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness, Lancet, 397, 2461, 10.1016/S0140-6736(21)01358-1

Thomas, 2021, Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months, medRxiv

Khoury, 2021, Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection, Nat Med, 27, 1205, 10.1038/s41591-021-01377-8

Heath, 2021, Safety and efficacy of NVX-CoV2373 Covid-19 vaccine, N Engl J Med, 385, 1172, 10.1056/NEJMoa2107659

Zhou, 2021, Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera, Cell, 184, 2348, 10.1016/j.cell.2021.02.037

Planas, 2021, Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies, Nat Med, 27, 917, 10.1038/s41591-021-01318-5

Chen, 2021, Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies, Nat Med, 27, 717, 10.1038/s41591-021-01294-w

Dejnirattisai, 2021, Antibody evasion by the P.1 strain of SARS-CoV-2, Cell, 184, 2939, 10.1016/j.cell.2021.03.055

Faulkner, 2021, Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains, eLife, 10, 10.7554/eLife.69317

Supasa, 2021, Reduced neutralization of SARS-CoV-2 B.1·1.7 variant by convalescent and vaccine sera, Cell, 184, 2201, 10.1016/j.cell.2021.02.033

Wang, 2021, Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization, Cell Host Microbe, 29, 747, 10.1016/j.chom.2021.04.007

Shen, 2021, SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines, Cell Host Microbe, 29, 529, 10.1016/j.chom.2021.03.002

Shen, 2021, Neutralization of SARS-CoV-2 variants B.1.429 and B.1.351, N Engl J Med, 384, 2352, 10.1056/NEJMc2103740

Becker, 2021, Immune response to SARS-CoV-2 variants of concern in vaccinated individuals, Nat Commun, 12, 10.1038/s41467-021-23473-6

Edara, 2021, Infection and vaccine-induced neutralizing-antibody responses to the SARS-CoV-2 B.1.617 variants, N Engl J Med, 385, 664, 10.1056/NEJMc2107799

Wall, 2021, Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination, Lancet, 397, 2331, 10.1016/S0140-6736(21)01290-3

Wall, 2021, AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC, Lancet, 398, 207, 10.1016/S0140-6736(21)01462-8

Khoury, 2020, Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models, Nat Rev Immunol, 20, 727, 10.1038/s41577-020-00471-1

Dan, 2021, Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection, Science, 371, 10.1126/science.abf4063

Goel, 2021, mRNA vaccination induces durable immune memory to SARS-CoV-2 and variants of concern, Science, 10.1126/science.abm0829

Anichini, 2021, SARS-CoV-2 antibody response in persons with past natural infection, N Engl J Med, 385, 90, 10.1056/NEJMc2103825

Leier, 2021, Previously infected vaccinees broadly neutralize SARS-CoV-2 variants, medRxiv

Stamatatos, 2021, mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection, Science, 372, 1413, 10.1126/science.abg9175

Goel, 2021, Distinct antibody and memory B cell responses in SARS-CoV-2 naive and recovered individuals following mRNA vaccination, Sci Immunol, 6, 10.1126/sciimmunol.abi6950

Lucas, 2021, Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity, Nature, 10.1038/s41586-021-04085-y

Choi, 2021, Serum neutralizing activity of mRNA-1273 against SARS-CoV-2 variants, bioRxiv

Wu, 2021, Preliminary analysis of safety and immunogenicity of a SARS-CoV-2 variant vaccine booster, medRxiv

Pan, 2021, Immunogenicity and safety of a third dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18–59 years: interim results from a double-blind, randomized, placebo-controlled phase 2 clinical trial, medRxiv

Evans, 2021, Vaccine effectiveness studies in the field, N Engl J Med, 385, 650, 10.1056/NEJMe2110605

Wheatley, 2021, Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19, Nat Commun, 12, 10.1038/s41467-021-21444-5

Li, 2021, A booster dose is immunogenic and will be needed for older adults who have completed two doses vaccination with CoronaVac: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial, medRxiv

Abu-Raddad, 2021, Protection afforded by the BNT162b2 and mRNA-1273 COVID-19 vaccines in fully vaccinated cohorts with and without prior infection, medRxiv

Cavanaugh, 2021, Reduced risk of reinfection with SARS-CoV-2 after COVID-19 vaccination—Kentucky, May–June 2021, MMWR Morb Mortal Wkly Rep, 70, 1081, 10.15585/mmwr.mm7032e1

Maxmen, 2021, COVID boosters for wealthy nations spark outrage, Nature, 10.1038/d41586-021-02109-1

Wheatley, 2021, Immune imprinting and SARS-CoV-2 vaccine design, Trends Immunol, 42, 956, 10.1016/j.it.2021.09.001